ODE II Director Jenkins Assumes Acting Title As Head Of E&M
Executive Summary
FDA Office of Drug Evaluation II Director John Jenkins, MD, is serving as acting director of FDA's Endocrine & Metabolic Drug Products Division following the departure Solomon Sobel, MD, to the Office of Review Management.
You may also be interested in...
FDA E&M Division Director Is Lipid Drug Team Leader Orloff
FDA's Endocrine & Metabolic Drug Products Division Director David Orloff, MD, brings six years of experience within the E&M division in reviewing lipid-regulating agents.
FDA E&M Division Director Is Lipid Drug Team Leader Orloff
FDA's Endocrine & Metabolic Drug Products Division Director David Orloff, MD, brings six years of experience within the E&M division in reviewing lipid-regulating agents.
FDA Defends Approvals After Divided Advisory Committee Votes In JAMA
FDA must continue to approve products when there is scientific disagreement evidenced by split advisory committee votes, agency officials declared in the Dec. 22/29 issue of the Journal of the American Medical Association.